SCHEMBL4930397

SCHEMBL4930397

NC(Cc1ccc(F)cc1)C(=O)N1CCC(CCCC(=O)NO)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.53
HDAC3 O15379 8/20 0.53
HDAC4 P56524 8/20 0.53
HDAC1 Q13547 8/20 0.53
HDAC7 Q8WUI4 8/20 0.53
HDAC2 Q92769 8/20 0.53
HDAC10 Q969S8 8/20 0.53
HDAC11 Q96DB2 8/20 0.53
HDAC8 Q9BY41 8/20 0.53
HDAC6 Q9UBN7 8/20 0.53
HDAC9 Q9UKV0 8/20 0.53
HDAC5 Q9UQL6 8/20 0.53
HRH2 P25021 1/20 0.46
HRH1 P35367 1/20 0.46
FAP Q12884 1/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
DPP7 Q9UHL4 1/20 0.46
AKT1 P31749 1/20 0.46
AKT2 P31751 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930402 1.00 DPP4 (0.53) DPP4HDAC3HDAC4HDAC1HDAC7
SCHEMBL4927992 0.89 HDAC3 (0.53) DPP4HDAC3HDAC4HDAC1HDAC7
SCHEMBL4915569 0.89 HDAC8 (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4916706 0.89 HDAC8 (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4915575 0.89 HDAC8 (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4929012 0.88 HDAC8 (0.54) DPP4HDAC3HDAC4HDAC1HDAC7
SCHEMBL4929008 0.88 HDAC8 (0.54) DPP4HDAC3HDAC4HDAC1HDAC7
SCHEMBL27703934 0.88 HDAC8 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4919555 0.87 HDAC3 (0.50) DPP4HDAC3HDAC4HDAC1HDAC7
SCHEMBL4919564 0.87 HDAC3 (0.50) DPP4HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US claimed
CN-101155780-A Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them MENARINI INT OPERATIONS LU SA (LU) 2008-04-02 CN claimed
EP-1868997-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Menarini International Operations Luxembourg S.A. (LU) 2007-12-26 EP claimed
WO-2006097460-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2006-09-21 WO claimed
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US disclosed
CN-101155780-A Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them MENARINI INT OPERATIONS LU SA (LU) 2008-04-02 CN disclosed
EP-1868997-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Menarini International Operations Luxembourg S.A. (LU) 2007-12-26 EP disclosed
WO-2006097460-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them HDAC1, HDAC8, HDAC9 DPP4 592/4885HDAC3 8/4885HDAC4 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.